KD-PACE salvage therapy for aggressive relapsed multiple myeloma

The non-cross-resistant combination VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide) incorporating novel and traditional anti-MM drugs has been evaluated for relapsed and/or refractory myeloma (RRMM) or aggressive clinical situations such as plasma cell leukemia (PCL) or extramedullary myeloma (EMM). However, in the modern era, many patients are already refractory to bortezomib when this therapy is utilized. Outcomes from incorporation of carfilzomib (KD-PACE) instead of bortezomib as salvage therapy for relapsed aggressive MM are described.